Exelixis Sees Higher Demand for Flagship Cancer Drug -- Market Talk

Dow Jones

2025/05/14

1707 ET - Exelixis's 1Q results crushed Wall Street's expectations after getting a boost from accelerating demand for its flagship Cabometyx cancer drug. Product revenue, composed almost entirely of Cabometyx sales, rose 36% in the quarter on higher volumes and prices, offsetting a 10% decline in collaboration revenues. The company expects such growth to continue, with its higher full-year outlook implying as much as 19% growth in product revenues from a year ago. Higher demand for the drug comes as it notches further support from the FDA, getting approval in March for treatment in previously treated advanced neuroendocrine tumors, adding to five previous approvals for the drug's use in other tumors. Shares rise 6.4% in after-hours trading. (kelly.cloonan@wsj.com)

(END) Dow Jones Newswires

May 13, 2025 17:07 ET (21:07 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2535853038"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535853038\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535853038?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-14 05:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535853038","market":"us","top_or_hot":-1,"title":"Exelixis Sees Higher Demand for Flagship Cancer Drug -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1707 ET - Exelixis's 1Q results crushed Wall Street's expectations after getting a boost from accelerating demand for its flagship Cabometyx cancer drug. Product revenue, composed almost entirely of Cabometyx sales, rose 36% in the quarter on higher volumes and prices, offsetting a 10% decline in collaboration revenues. The company expects such growth to continue, with its higher full-year outlook implying as much as 19% growth in product revenues from a year ago. Higher demand for the drug comes as it notches further support from the FDA, getting approval in March for treatment in previously treated advanced neuroendocrine tumors, adding to five previous approvals for the drug's use in other tumors. Shares rise 6.4% in after-hours trading. (kelly.cloonan@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 13, 2025 17:07 ET (21:07 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exelixis Sees Higher Demand for Flagship Cancer Drug -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExelixis Sees Higher Demand for Flagship Cancer Drug -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-05-14 05:07</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1707 ET - Exelixis's 1Q results crushed Wall Street's expectations after getting a boost from accelerating demand for its flagship Cabometyx cancer drug. Product revenue, composed almost entirely of Cabometyx sales, rose 36% in the quarter on higher volumes and prices, offsetting a 10% decline in collaboration revenues. The company expects such growth to continue, with its higher full-year outlook implying as much as 19% growth in product revenues from a year ago. Higher demand for the drug comes as it notches further support from the FDA, getting approval in March for treatment in previously treated advanced neuroendocrine tumors, adding to five previous approvals for the drug's use in other tumors. Shares rise 6.4% in after-hours trading. (kelly.cloonan@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 13, 2025 17:07 ET (21:07 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2535853038","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535853038","pubTimestamp":1747170420,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1707 ET - Exelixis's 1Q results crushed Wall Street's expectations after getting a boost from accelerating demand for its flagship Cabometyx cancer drug. Product revenue, composed almost entirely of Cabometyx sales, rose 36% in the quarter on higher volumes and prices, offsetting a 10% decline in collaboration revenues. The company expects such growth to continue, with its higher full-year outlook implying as much as 19% growth in product revenues from a year ago. Higher demand for the drug comes as it notches further support from the FDA, getting approval in March for treatment in previously treated advanced neuroendocrine tumors, adding to five previous approvals for the drug's use in other tumors. Shares rise 6.4% in after-hours trading. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","EXEL":"伊克力西斯","BK4532":"文艺复兴科技持仓"},"translate_title":"Exelixis看到对旗舰癌症药物的需求更高——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXEL":1},"content_text":"1707 ET - Exelixis's 1Q results crushed Wall Street's expectations after getting a boost from accelerating demand for its flagship Cabometyx cancer drug. Product revenue, composed almost entirely of Cabometyx sales, rose 36% in the quarter on higher volumes and prices, offsetting a 10% decline in collaboration revenues. The company expects such growth to continue, with its higher full-year outlook implying as much as 19% growth in product revenues from a year ago. Higher demand for the drug comes as it notches further support from the FDA, getting approval in March for treatment in previously treated advanced neuroendocrine tumors, adding to five previous approvals for the drug's use in other tumors. Shares rise 6.4% in after-hours trading. (kelly.cloonan@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 13, 2025 17:07 ET (21:07 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}